Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0087 • ACR Convergence 2024
SYNCAR: An Engineered IL-2/IL-2R-system That Selectively Enhances CD19 CAR T Cells to Deplete B Cells and Provide Therapeutic Benefit in SLE and RA Mouse Models Without Lymphodepletion
Ethan Jung¹, Marie semana¹, Ivan Cheng¹, Helena Silva¹, Sandro Vivona¹, Somya Singh¹, Michele Bauer¹, Mohammed Ali¹, Henry Rosas¹, Woei Chang¹, Deepti Rokkam¹, Patrick Lupardus¹, Martin Oft¹ and Paul-Joseph Aspuria², ¹Synthekine, Menlo Park, ²Sythekine, Menlo Park, CA
Background/Purpose: CD19 CAR-T therapy has demonstrated efficacy in autoimmune (AI) diseases like systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing its potential beyond oncology.…
Abstract Number: 0202 • ACR Convergence 2024
Survival in Patients with Rheumatoid Arthritis and Early-Stage Colorectal, Lung, or Prostate Cancer Receiving Tumor Necrosis Factor Alpha Inhibitors
Maria Suarez-Almazor¹, Juan Ruiz², Xiudong Lei¹, Hui Zhao¹, Suja Rajan³, Heather Lin¹ and Sharon Giordano¹, ¹MD Anderson Cancer Center, Houston, TX, ²MD Anderson, Houston, TX, ³The University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: There is concern about the use of tumor necrosis factor inhibitors (TNFi) in patients with early cancer given their immunosuppressant effects. Few studies have…
Abstract Number: 0310 • ACR Convergence 2024
I-CARE Program: Interest of Multidisciplinary Systematic Screening Program for Comorbidities for Patients Suffering from Arthritis Rheumatoid DiseasE: A Real Life Study
Amine Mouamnia, Armentieres Hospital Center, Armentieres, France
Background/Purpose: Inflammatory and auto-immune disease are associated to comordities. Indeed, patients suffering from arthritis rheumatoid disease (ARD) such as rheumatoid arthritis (RA), polymyalgia rheumatica (PMR)…
Abstract Number: 0449 • ACR Convergence 2024
Evaluating Premenstrual Dysphoric Disorder in Women with Rheumatoid Arthritis and Healthy Female Subjects
Ana Cecilia Bardan-Inchaustegui¹, Iris Jazmín Colunga Pedraza², Rosa Icela Arvizu-Rivera², Gisela Garcia-Arellano³, Griselda Serna-Peña⁴, Maria F. Elizondo-Benitez⁵, Aleydis Gonzalez Melendez², Fernanda Massiel Garcia⁶ and Dionicio Galarza-Delgado⁷, ¹Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³Hospital Universitario \"Dr. José Eleuterio González\", Monterrey, Nuevo León, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", UANL, Monterrey, Mexico, ⁵Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁶Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico, ⁷UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Premenstrual dysphoric disorder (PMDD), a severe form of premenstrual syndrome, is classified as a psychiatric disorder characterized by moderate to severe physical, affective, or…
Abstract Number: 0471 • ACR Convergence 2024
Understanding the Role of the Complement System in Insulin Resistance and Metabolic Syndrome in Patients with Rheumatoid Arthritis
Jose Viotti-Serra¹, Maria Garcia-Gonzalez², Fuensanta Gomez-Bernal¹, Juan Carlos Quevedo-Abeledo³, Miguel Angel Gonzalez-Gay⁴ and ivan Ferraz-Amaro⁵, ¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ²Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, ³Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, ⁴University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁵Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain
Background/Purpose: The complement (C) system has been associated with the etiopathogenesis of rheumatoid arthritis (RA). Insulin resistance (IR) and metabolic syndrome are prevalent among RA…
Abstract Number: 0488 • ACR Convergence 2024
Association of Anti-CarP Levels with Clinical Activity and Serological Profile in Rheumatoid Arthritis
Pablo Martínez Calabuig¹, Elena Grau García², Samuel Leal Rodriguez², Ernesto Tovar Sugrañes³, José Ivorra-Cortés⁴, Carmen Riesco Barcena³, Anderson Huaylla Quispe³, Laura Mas Sánchez⁵, Pablo Muñoz Martínez⁶, Daniel Ramos Castro³, Alba Torrat noves⁷, Iago Alcantara Alvarez⁸, Belén Villanueva Mañés⁸, Miguel Simeo Vinaixa⁸, Andrés Pérez Hurtado³ and Jose A Román-Ivorra⁹, ¹HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, ²HUP La Fe, Valencia, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Spain, ⁴Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, ⁵Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ⁶Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ⁷Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁹Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease where the presence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (antiCCP) has been associated to…
Abstract Number: 0505 • ACR Convergence 2024
UseofaMolecularSignatureResponseClassifiertoPredictInadequateResponsetoTNFiResultsinFewer Patients Prescribed TNFi
George Karpouzas¹, Lixia Zhang², Mark Zielinski², Brian Cheng² and Sherry Guardiano³, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Scipher Medicine Corporation, Waltham, MA, ³Scipher Medicine Corporation, Keene, NH
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are generally the first class of biologic disease modifying anti-rheumatic drugs (DMARDs) prescribed for rheumatoid arthritis (RA) patients with…
Abstract Number: 0522 • ACR Convergence 2024
Hematological Impact Assessment of Tofacitinib, Baricitinib, and Upadacitinib in Rheumatoid Arthritis Treatment
Soo Min Ahn, Mi-Ra Cho, Ji Seon Oh, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo and Seokchan Hong, Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Janus kinase (JAK) inhibitors' introduction has significantly revolutionized the therapeutic landscape, notably influencing the management strategies for rheumatoid arthritis (RA). To compare the effects…
Abstract Number: 0678 • ACR Convergence 2024
Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually
Oliver Distler¹, Margarida Alves², Gerrit Toenges³ and Anna-Maria Hoffmann-Vold⁴, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ²Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ³Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁴Oslo University Hospital, Oslo, Norway
Background/Purpose: There is no consensus on the frequency of monitoring of patients with autoimmune disease-related interstitial lung diseases (ILDs), but a frequency of 1 year…
Abstract Number: 0871 • ACR Convergence 2024
Disease-associated Central Nervous System Activation Predicts Good Clinical Response to Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis Patients – “The PreCePRA Study”
Juergen Rech¹, Prof. Dr. Andreas Hess², Koray Tascilar¹, Dr. Hannah Schenker³, verena schönau¹, Marina Sergeeva², Jutta Prade², Silke Kreitz², Mageshva Sulvakumar², Laura Konerth², Sandra Strobelt², Matthias Englbrecht⁴, Prof. Dr. Dr. Axel Hueber⁵, Eugen Feist⁶, Prof. Dr. Mario Zaiss¹, Gerd Burmester⁷, Frank Behrens⁸, Dr. Michaela Koehm⁹, Prof. Dr. Christoph Baerwald¹⁰, Dr. Stephanie Finzel¹¹, Dr. Arnd Kleyer¹², Prof. Dr. Reinhard Voll¹¹, Dr. Julie Roesch¹³, Prof. Dr. Arnd Doerfler¹³, Prof. Dr. Nemanja Damjanov¹⁴, Prof. José António P. Da Silva¹⁵ and Georg Schett¹⁶, ¹Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ²Institute for Experimental Pharmacology FAU Erlangen-Nürnberg, Erlangen, Germany, ³Department of Internal Medicine 3 - Rheumatology and Immunology, Department of Internal Medicine 1 - Gastroenterology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Freelance Healthcare Data Scientist, Eckental, ⁵Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, + Rheumatologie, Klinik für Innere Medizin 5, Klinikum Nürnberg Nord, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Deutschland, Erlangen, Germany, ⁶Department of Rheumatology, Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Gommern, Germany, ⁷Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁸University Hospital Goethe University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ⁹Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, ¹⁰Medizinische Klinik III - Bereich Rheumatologie, Liebigstraße 20, 04103 Leipzig, Leipzig, Germany, ¹¹Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Hugstetterstraße 55, 79106 Freiburg, Freiburg, Germany, ¹²Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany; Charité - Universitätsmedizin Berlin Med. Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie Berlin, Erlangen, Germany, ¹³Department of Neuroradiology, Friedrich - Alexander - Universitaet Erlangen - Nuernberg and Universitaetsklinikum Erlangen , Erlangen , Germany, Erlangen, Germany, ¹⁴Belgrade University School of Medicine, Institute Institute of Rheumatology, Belgrade, Belgrade, Serbia, ¹⁵Head of Department Reumatologia. Hospitais da Universidade (SRHUC), Coimbra, Portugal, ¹⁶Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Rheumatoid arthritis (RA) is an chronic inflammatory disease that is frequently treated with tumor necrosis factor inhibitors (TNFi). Little is known about predictors of…
Abstract Number: 0936 • ACR Convergence 2024
Schnurri-3 Inhibition Protects from NF-kB-induced Bone Loss in Inflammatory Arthritis
Priyanka Kushwaha¹, Catherine Manning², Tadatoshi Sato³, Yeon-Suk Yang³, Jae-Hyuck Shim⁴ and Ellen Gravallese⁵, ¹Department of Medicine/Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Boston, MA, ²Brigham and Women's Hospital, Dedham, MA, ³Department of Medicine/Division of Rheumatology, Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA, ⁴University of Massachusetts, Worcester, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: In rheumatoid arthritis (RA), production of TNF promotes osteoclast activity and inhibits osteoblasts (OBs) and bone healing. Schnurri-3 (SHN3) is a potent suppressor of…
Abstract Number: 0983 • ACR Convergence 2024
Life Satisfaction in Adults Living with Arthritis – a Cross-Sectional Analysis of the 2022 National Health Interview Survey
Aleksander Lenert¹, Mary E. Charlton¹, Jacob J. Oleson¹, Robyn Domsic² and Polly Ferguson³, ¹University of Iowa, Iowa City, IA, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: General well-being, an individual’s subjective assessment of their life overall, may be impacted by arthritis. It is unclear if adults with arthritis have lower…
Abstract Number: 1041 • ACR Convergence 2024
A Theory of Change for Patient-Initiated Follow-Up Care in Rheumatoid Arthritis
Manuel Ester¹, Krista White², Kiran Dhiman², Saania Zafar², Alexandra Charlton³, Glen Hazlewood⁴, Gabrielle L. Zimmermann⁵, Alison Hoens⁶, Sarah L. Manske⁷, Diane Lacaille⁸, Mark G. Perry⁹, Megan R.W. Barber¹⁰, Aurore Fifi-Mah⁴, Niki Panich¹¹, Monika Szpunar¹², Karen Then¹³, Kelly Osinski¹⁴, Shakeel Subdar¹⁵, Hafsah Al-Azem¹⁶, Michelle Jung¹⁶ and Claire Barber⁴, ¹McCaig Institute for Bone and Joint Health, Cumming School of Medicine, University of Calgary; O’Brien Institute for Public Health, Cumming School of Medicine, University of Calgary; Arthritis Research Canada, Calgary, AB, Canada, ²McCaig Institute for Bone and Joint Health, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Division of Rheumatology, Cumming School of Medicine, Calgaru, AB, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵Alberta SPOR SUPPORT Unit – Learning Health System Team, Department of Medicine, University of Alberta; 6. Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Edmonton, AB, Canada, ⁶Arthritis Research Canada; Department of Physical Therapy, University of British Columbia, Vancouver, BC, Canada, ⁷McCaig Institute for Bone and Joint Health, Cumming School of Medicine, University of Calgary; Department of Radiology, University of Calgary, Calgary, AB, Canada, ⁸Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁹Department of Rheumatology, University Hospitals Plymouth; Peninsula Medical School, Plymouth, England, United Kingdom, ¹⁰Arthritis Research Canada; Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ¹¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹²Arthritis Research Canada, Toronto, ON, Canada, ¹³Faculty of Nursing, University of Calgary, Calgary, AB, Canada, ¹⁴Alberta Health Services, Edmonton, AB, Canada, ¹⁵Temerty School of Medicine, University of Toronto, Toronto, ON, Canada, ¹⁶Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada
Background/Purpose: Timely, high-quality care is critical to effective rheumatoid arthritis (RA) management. Due to the resource-intensive nature of routine lifelong follow-ups and rheumatologist shortages, RA…
Abstract Number: 1248 • ACR Convergence 2024
Most Prevalent Self-Reported Comorbidities Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis
Shilpa Venkatachalam¹, Jeffrey Curtis², Anne Sydor³, Erik Stone⁴, Angela Degrassi³, Esteban Rivera⁵, Laura Stradford⁶ and Kelly Gavigan³, ¹Global Healthy Living Foundation, New York, NY, ²University of Alabama at Birmingham, Hoover, AL, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, Upper Nyack, ⁵Global Healthy Living Foundation, Long Island City, NY, ⁶Global Healthy Living Foundation, Nyack, NY
Background/Purpose: Many people with inflammatory arthritis live with other serious chronic conditions that may affect their quality of life and ability to effectively manage their…
Abstract Number: 1337 • ACR Convergence 2024
Gender and Ethnic Differences (or Lack Thereof) in Perceived Disease Burden in RA
Ali Malik¹, Dennis Ang¹, Adam Hall¹, John Herion¹ and Rupak Thapa², ¹Wake Forest University, Winston Salem, NC, ²Assistant Professor, Winston Salem, NC
Background/Purpose: Gender and ethnic disparities in health care are well reported in the general medical literature. Differences in symptom reporting or perceived health status can…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].